Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects

British Journal of Clinical Pharmacology

Volumn 60, Issue 4, 2005, Pages 404-413

  Hanna, Julia ^a   Foster, David J R ^a   Salter, Amy ^a   Somogyi, Andrew A ^a,b   White, Jason M ^a   Bochner, Felix ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Enantiomers; Methadone; Pharmacodynamics; Pharmacokinetics; Within and between subject variability

Indexed keywords

METHADONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREATHING RATE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MENTAL INSTABILITY; METHADONE TREATMENT; PAIN; PRIORITY JOURNAL; PUPIL; STEADY STATE; WITHDRAWAL SYNDROME;

ADULT; AREA UNDER CURVE; FEMALE; HEART RATE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; PUPIL; QUESTIONNAIRES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 26444552838     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02464.x     Document Type: Article

References (54)

1. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1977; 21: 147-57.
2. Isbell H, Eisenman AJ. The addiction liability of some of the drugs of the methadon series. J Pharmacol Exp Ther 1948; 93: 305-13.
3. Scherbaum N, Finkbeiner T, Leifert K, Gastpar M. The efficacy of L-methadone and racemic methadone in substitution treatment for opiate addicts - a double-blind comparison. Pharmacopsychiatry 1996; 29: 212-5.
4. Meresaar U, Nilsson MI, Holmstrand J, Änggård E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol 1981; 20: 473-8.
5. Foster DJR, Somogyi AA, White JM, Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 2004; 57: 742-55.
6. Wolff K, Rostami-Hodjegan A, Shires S, Hay AWM, Feely M, Calvert R, Raistrick D, Tucker GT. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997; 44: 325-34.
7. Farrell M, Ward J, Mattick R, Hall W, Stimson G, des Jarlais D, Gossop M, Strang J. Methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309: 997-1001.
8. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969; 280: 1372-5.
9. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 2: 485-8.
10. Gunne L-M, Grönbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981; 7: 249-56.
11. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119: 23-7.
12. Dyer KR, White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997; 92: 1445-55.
13. Dyer KR, Foster DJR, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65: 685-94.
14. Dyer KR, White JM, Foster DJR, Bochner F, Menelaou A, Somogyi AA. The relationship between mood state and plasma methadone concentration in methadone maintenance patients. J Clin Psychopharmacol 2001; 21: 78-84.
15. Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 2004; 99: 940-5.
16. Newcombe DLA, Bochner F, White JM, Somogyi AA. Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal. Drug Alcohol Depend 2004; 76: 63-72.
17. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33: 313-22.
18. Eap CB, Buclin T, Baumann P. Interindividual Variability of the Clinical Pharmacokinetics of Methadone. Implications for the Treatment of Opioid Dependence. Clin Pharmacokinet 2002; 41: 1153-93.
19. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002; 5: 127-38.
20. Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust 2000; 173: 536-40.
21. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs 2001; 61: 955-77.
22. Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47: 403-12.
23. Shiran MR, Lennard MS, Iqbal MZ, Langundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 activities and plasma methadone concentrations in patients undergoing methadone maintenance treatment (MMT). 8th World Congress on Clinical Pharmacology and Therapeutics, Brisbane, Australia. Clin Exp Pharmacol Physiol 2004; 31: A154.
24. Gourlay GK, Wilson PR, Glynn G. Methadone produces prolonged postoperative analgesia. Br Med J (Clin Res Edition) 1982; 284: 630-1.
25. Gourlay GK, Willis RJ, Wilson PR. Postoperative pain control with methadone: influence of supplementary methadone doses and blood concentration-response relationships. Anesthesiology 1984; 61: 19-26.
26. Gourlay GK, Willis RJ, Lamberty J. A double-blind comparison of the efficacy of methadone and morphine in postoperative pain control. Anesthesiology 1986; 64: 322-7.
27. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986; 25: 297-312.
28. Inturrisi C, Portenoy R, Max M, Colburn W, Foley K. Methadone infusions: pharmacokinetic-phaimacodynamic (PK-PD) relationships. The 88th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Florida USA. Clin Pharmacol Therapeutics 1987; 41: 211.
29. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392-401.
30. Inturrisi CE, Portenoy RK, Max MB, Colburn WA, Foley KM. Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 1990; 47: 565-77.
31. Verebely K, Kutt H. Methadone plasma levels in maintenance patients: the effect of dose omission. Res Commun Chem Pathol Pharmacol 1975; 11: 373-86.
32. Hiltunen AJ, Beck O, Hjemdahl P, Liljeberg P, Almström U, Brodin K, von Wachenfeldt J, Borg S. Rated well-being in relation to plasma concentrations of I- and d- methadone in satisfied and dissatisfied patients on methadone maintenance treatment. Psychopharmacology 1999; 143: 385-93.
33. Nilsson MI, Grönbladh L, Widerlov E, Änggård E. Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. Eur J Clin Pharmacol 1983; 25: 497-501.
34. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-7.
35. Haertzen C, Hickey J. Addiction Research Center Inventory (ARCI): measurement of euphoria and other drug effects. In: Methods of Assessing the Reinforcing Properties of Abused Drugs. Bozarth M (ed). New York: Springer-Verlag, 1987: pp. 489-524.
36. McNair DM, Lorr M, Droppleman L. EITS Manual for the Profile of Mood States. 1971 Educational and Industrial Testing Service; San Diego, USA.
37. Foster DJR, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R) - and (S) -methadone in methadone maintenance patients. Br J Clin Pharmacol 2000; 50: 427-40.
38. Laird NM, Ware JH. Random-Effects Models for Longitudinal Data. Biometrics 1982; 38: 963-74.
39. de Vos JW, Geerlings PJ, van den Brink W, Ufkes JG, van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995; 48: 361-6.
40. Eap CB, Bertschy G, Baumann P, Finkbeiner T, Gastpar T, Gastpar M, Scherbaum N. High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry 1998; 55: 89-90.
41. Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi AA, Bochner F, White JM. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- versus (R) -methadone exposure. Br J Clin Pharmacol 2004; 58: 609-17.
42. Norberg A, Gabrielsson J, Jones AW, Hahn RG. Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. Br J Clin Pharmacol 2000; 49: 399-408.
43. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000; 40: 123-7.
44. Siegmund W, Ludwig K, Engel G, Zschiesche M, Franke G, Hoffmann A, Terhaag B, Weitschies W. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J Pharm Sci 2003; 92: 604-10.
45. Arlander E, Sjövall J, Sörstad J, Norsten-Höög C, Gustafsson LL. Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability. Br J Clin Pharmacol 2003; 55: 14-22.
46. Tett S, Day R, Cutler D. Hydroxychloroquine relative bioavailability: within subject reproducibility. Br J Clin Pharmacol 1996; 41: 244-6.
47. Hande K, Messenger M, Wagner J, Krozely M, Kaul S. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999; 5: 2742-7.
48. Marathe PH, Greene DS, Lee JS, Barbhaiya RH. Assessment of effect of food, gender, and intra-subject variability in the pharmacokinetics of avitriptan. Biopharm Drug Dispos 1998; 19: 153-7.
49. Eichelbaum M, Somogyi A. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol 1984; 26: 47-53.
50. Tsang YC, Pop R, Gordon P, Hems J, Spino M. High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil. Pharm Res 1996; 13: 846-50.
51. Grahnen A, Hammarlund M, Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 1984; 27: 595-602.
52. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76: 119-27.
53. Boulton DW, Arnaud P, DeVane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 2001; 70: 48-57.
54. Somogyi A. Pharmacogenetics of opioid analgesia: interplay between genes, enzymes, transporters and receptors. 2nd Annual Meeting of the International Society of Pharmacogenomics, Los Angeles, 2003.